Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    9817107 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Evaluation of a Telephone Follow-up Procedure on the Quality of Life in Psychogenic Non-epileptic Seizures
Condition: Psychogenic Non Epileptic Seizure
Intervention: Other: Telephone follow-up device
2 Terminated Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study
Conditions: Emphysema;   Chronic Obstructive Pulmonary Disease
Intervention: Device: Emphasys Endobronchial Valve (EBV) Device and Procedure
3 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36

Indicates status has not been verified in more than two years